

Andrew M Waters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5295394/publications.pdf>

Version: 2024-02-01

13
papers

1,488
citations

933447

10
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

3407
citing authors

#	ARTICLE	IF	CITATIONS
1	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031435.	6.2	563
2	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	30.7	476
3	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
4	Differential Effector Engagement by Oncogenic KRAS. Cell Reports, 2018, 22, 1889-1902.	6.4	101
5	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
6	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling, 2017, 10, .	3.6	51
7	Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 2016, 7, 86948-86971.	1.8	23
8	Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer Research, 2022, 82, 90-104.	0.9	19
9	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports, 2021, 35, 109291.	6.4	15
10	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Reports, 2021, 37, 110060.	6.4	14
11	Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells. PLoS ONE, 2016, 11, e0163272.	2.5	10
12	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 762-774.	4.1	9
13	Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in Molecular Biology, 2021, 2262, 91-103.	0.9	2